Introduction
immunodeficient, cancers, immunocompetent, tumor
VIRUS, CANCERS, TUMOR, PROLIFERATION, LATENT INFECTION, SOLID TUMORS
Epstein-Barr virus (EBV) is a human γ-herpesvirus that establishes long-term latent infection in over 90% of the adult population worldwide and is a causal factor for many lymphoid and epithelial cancers in both immunodeficient and immunocompetent patients.EBVEBV offers an attractive, druggable nonhost target, but is predominantly latent in infected tumor cells, and most of the ∼80 protein-coding viral genes are epigenetically silenced, except for a small subset that is necessary for the maintenance and replication of the episome (EBNA1), to drive host cell proliferation, and to block apoptotic pathways (LMP-1, LMP-2A).Nanatinostat (VRx-3996; CHR-3996; Nstat) is a potent, orally administered hydroxamic acid-based class I-selective HDACi highly selective for HDAC 1 to 3, with a single-agent maximum tolerated dose of 80 mg per day in patients with advanced solid tumors and a recommended phase 2 dose (RP2D) of 40 mg/d.This international multicenter phase 1b/2 VT3996 to 201 study (NCT03397706) is the first clinical study to evaluate Nstat with VGCV in patients with EBV